LifeMD GLP-1 at a glance: A publicly-traded virtual primary care and weight management platform. LifeMD, Inc. (Nasdaq: LFMD) parent. $79/month Weight Management Program subscription (medication priced separately). FDA-approved GLP-1 lineup coordinated through insurance: Wegovy · Zepbound · Ozempic · Mounjaro. Dedicated insurance navigation team handles prior authorization. 50-state coverage. NCQA Patient-Centered Connected Care recognition. Named medical leadership: Chief Medical Officer Dr. Anthony Puopolo MD + Dr. Naheed Ali MD PhD. LifeMD app for video follow-ups + messaging + dose-titration support. Broader integrated telehealth menu (Primary Care + Mental Health + Men's Health + Hair + Skin + Insomnia + Allergy + B12 + Concierge). Best for buyers with commercial or Medicare insurance who want FDA-approved branded GLP-1 + insurance navigation + Nasdaq-listed parent infrastructure. Skip if you want the cheapest possible cash-pay compounded GLP-1 without insurance coordination.
✓ Pick LifeMD GLP-1 if
You have commercial or Medicare insurance and want active prior-authorization navigation for Wegovy / Zepbound / Ozempic / Mounjaro; you value Nasdaq-listed parent (LifeMD, Inc., LFMD); you want FDA-approved branded GLP-1 only (no compounded); you appreciate the NCQA Patient-Centered Connected Care recognition; you want named medical leadership (Dr. Puopolo CMO + Dr. Ali); you value the integrated multi-vertical telehealth platform (Primary Care + Mental Health + Men's Health alongside GLP-1); you want 50-state coverage with board-certified U.S. clinicians.
✕ Skip LifeMD GLP-1 if
You want the cheapest possible cash-pay compounded GLP-1; you do not have commercial or Medicare insurance and prefer transparent published flat-rate pricing; you do not want to pay a $79/month subscription on top of medication cost; you want a 365-day GLP-1 money-back warranty; you have GLP-1 contraindications; or you are not comfortable with insurance prior-authorization timelines (typically 5-21 days).
Our verdict on LifeMD GLP-1
- Best for
- Buyers with commercial or Medicare insurance who want FDA-approved branded GLP-1 + active prior-authorization handling + Nasdaq-listed parent + named medical leadership.
- GLP-1 strengths
- LifeMD, Inc. publicly-traded parent (Nasdaq: LFMD) with SEC reporting and corporate-governance transparency; $79/month Weight Management subscription separates clinical-care fee from medication cost; FDA-approved branded GLP-1 menu (Wegovy + Zepbound + Ozempic + Mounjaro) coordinated through insurance; dedicated in-house insurance navigation team handles prior authorization; NCQA Patient-Centered Connected Care recognition; named medical leadership including Chief Medical Officer Dr. Anthony Puopolo MD + Dr. Naheed Ali MD PhD; 50-state plus Washington D.C. coverage with board-certified U.S. clinicians; LifeMD app for ongoing video visits + messaging + dose-titration support; broader integrated telehealth menu (Primary Care + Mental Health + Men's Health + Hair + Skin + Insomnia + Allergy + B12 + Concierge); comprehensive published Terms of Use + Privacy Notice + Telehealth Consent + Notice of Privacy Practices; Investor Relations at ir.lifemd.com; published Newsroom + Leadership + Careers pages.
- GLP-1 drawbacks
- $79/month subscription is in addition to (not inclusive of) GLP-1 medication cost; FDA-approved branded GLP-1 retail pricing without insurance coverage is materially higher than cash-pay compounded GLP-1; medication access for Ozempic / Mounjaro requires clinical eligibility (type 2 diabetes) per FDA-approved labeling; no published 365-day GLP-1 money-back warranty; prior-authorization timelines vary by insurance plan (typically 5-21 days).
- GLP-1 pricing
- Weight Management Program: $79/month (medication priced separately). FDA-approved GLP-1 cost depends on insurance plan benefits and prior-authorization outcome.
- Editor's rating
- 4.4 / 5 — Distinctive positioning: Nasdaq-listed parent + in-house insurance navigation + named medical leadership + integrated multi-vertical telehealth platform.
Start LifeMD's GLP-1 program today
FDA-approved Wegovy + Zepbound + Ozempic + Mounjaro. Dedicated insurance navigation. Dr. Puopolo CMO. Nasdaq: LFMD parent. NCQA recognized.
Visit LifeMD's Official Site →The FDA-approved GLP-1 lineup — 4 medications
Coverage note: Wegovy and Zepbound are FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Ozempic and Mounjaro are FDA-approved for type 2 diabetes and are available only to patients who meet the clinical eligibility criteria, as determined by a licensed LifeMD clinician. Out-of-pocket cost depends on the member's specific commercial or Medicare-Advantage plan benefits and prior-authorization outcome.
How the insurance navigation works
LifeMD's structural differentiator vs cash-pay compounded GLP-1 platforms is the dedicated insurance navigation team. The workflow:
- Initial intake at lifemd.com/weight-management. Includes BMI, weight history, comorbidities, current medications, and insurance details.
- Video visit with a board-certified LifeMD clinician — typically 20-30 minutes. Clinician determines which FDA-approved GLP-1 (if any) is medically appropriate.
- Prior authorization (PA) — LifeMD's in-house insurance team prepares and submits PA documentation directly to your commercial or Medicare-Advantage plan.
- Pharmacy fulfillment — once approved, the prescription is routed to your preferred retail or specialty pharmacy. PA timelines vary by plan, typically 5-21 days.
- Ongoing care — monthly $79 subscription covers follow-up video visits, dose-titration support, and side-effect management via the LifeMD app.
Named medical leadership
LifeMD publishes named medical leadership, which is editorially material for a Nasdaq-listed telehealth platform. Key disclosed roles:
- Dr. Anthony Puopolo, MD — Chief Medical Officer. Board-certified family medicine; oversees clinical quality and care-team protocols across LifeMD's multi-vertical practice.
- Dr. Naheed Ali, MD PhD — Editorial reviewer for LifeMD's published clinical education content.
- Board-certified U.S. clinician network — licensed across all 50 states plus D.C., supporting Primary Care + Weight Management + Men's Health + Mental Health + adjacent verticals.
What we verified about LifeMD GLP-1
| What we checked | What we found |
|---|---|
| Brand & entity VERIFIED | LifeMD, Inc. · © 2026 All rights reserved |
| Domain VERIFIED | lifemd.com |
| Nasdaq: LFMD publicly traded VERIFIED | Investor Relations: ir.lifemd.com |
| NCQA Patient-Centered Connected Care recognition VERIFIED | Verifiable at reportcards.ncqa.org |
| Weight Management Program subscription VERIFIED | $79/month (medication priced separately) |
| Dedicated insurance navigation team VERIFIED | In-house prior-authorization handling |
| FDA-approved Wegovy VERIFIED | Semaglutide for chronic weight management |
| FDA-approved Zepbound VERIFIED | Tirzepatide for chronic weight management |
| FDA-approved Ozempic VERIFIED | Semaglutide — T2D eligibility required |
| FDA-approved Mounjaro VERIFIED | Tirzepatide — T2D eligibility required |
| Dr. Anthony Puopolo MD CMO VERIFIED | Board-certified family medicine |
| Dr. Naheed Ali MD PhD VERIFIED | Editorial reviewer for clinical content |
| 50-state coverage + Washington D.C. VERIFIED | Board-certified U.S. clinician network |
| LifeMD app VERIFIED | iOS + Android — video follow-ups + messaging |
| Multi-vertical telehealth menu VERIFIED | Primary Care + Mental Health + Men's Health + Hair + Skin + Insomnia + Allergy + B12 + Concierge |
| Investor Relations VERIFIED | ir.lifemd.com |
| Newsroom + Leadership + Careers VERIFIED | Comprehensive corporate infrastructure |
| Terms of Use + Privacy Notice + Telehealth Consent VERIFIED | Comprehensive published |
| Notice of Privacy Practices VERIFIED | HIPAA-compliant disclosure |
| Medication cost separate from $79 subscription CAUTION | Combined total depends on insurance outcome |
| FDA-approved retail pricing without insurance CAUTION | Materially higher than cash-pay compounded |
| Prior-authorization timeline CAUTION | Typically 5-21 days; varies by plan |
| 365-day money-back GLP-1 warranty CAUTION | Not published |
All claims verified on lifemd.com as of June 2026. LifeMD's combination of Nasdaq-listed parent + NCQA recognition + in-house insurance navigation + named medical leadership is editorially distinctive for FDA-approved branded GLP-1 delivery.
Are LifeMD's GLP-1 medications compounded or FDA-approved?
LifeMD's GLP-1 lineup is FDA-approved branded: Wegovy (semaglutide), Zepbound (tirzepatide), Ozempic (semaglutide), and Mounjaro (tirzepatide). These are coordinated through commercial or Medicare-Advantage insurance via LifeMD's dedicated prior-authorization team. The platform is not built around direct-to-consumer compounded GLP-1.
The 2026 GLP-1 regulatory landscape
The FDA resolved the official semaglutide GLP-1 shortage in early 2025 and similarly resolved the tirzepatide shortage shortly thereafter. Per FDA guidance on Section 503A and 503B compounding, mass compounding of essentially identical copies of commercially available drugs is generally not permitted outside narrow patient-specific exceptions. LifeMD's FDA-approved-branded model is structurally insulated from compounded-supply tightening.
LifeMD GLP-1 pros and cons
✓What we like
- Nasdaq-listed parent LifeMD, Inc. (Nasdaq: LFMD) — SEC-reporting transparency
- NCQA Patient-Centered Connected Care recognition
- $79/month Weight Management Program — separates clinical-care fee from medication cost
- FDA-approved GLP-1 menu: Wegovy + Zepbound + Ozempic + Mounjaro
- Dedicated in-house insurance navigation team — handles prior authorization for commercial & Medicare-Advantage
- Named medical leadership: Dr. Anthony Puopolo MD CMO + Dr. Naheed Ali MD PhD
- 50-state plus D.C. coverage with board-certified U.S. clinicians
- LifeMD app: video follow-ups + messaging + dose-titration support
- Broader integrated telehealth menu: Primary Care + Mental Health + Men's Health + Hair + Skin + Insomnia + Allergy + B12 + Concierge
- Comprehensive Terms of Use + Privacy Notice + Telehealth Consent + Notice of Privacy Practices
- Investor Relations + Newsroom + Leadership + Careers pages published
✕Where LifeMD GLP-1 falls short
- $79/month subscription is in addition to (not inclusive of) medication cost
- FDA-approved branded GLP-1 retail pricing without insurance is materially higher than cash-pay compounded
- Ozempic / Mounjaro access requires type 2 diabetes clinical eligibility per FDA-approved labeling
- Prior-authorization timeline varies by plan (typically 5-21 days)
- No published 365-day GLP-1 money-back warranty
- Compounded GLP-1 is not the platform's primary path
Start with LifeMD today
Nasdaq: LFMD. NCQA recognized. Dedicated insurance navigation. FDA-approved Wegovy + Zepbound + Ozempic + Mounjaro. Dr. Puopolo CMO.
Visit LifeMD's Official Site →LifeMD GLP-1 sign-up & ongoing-care checklists
Before sign-up
- Verify Nasdaq: LFMD + NCQA recognition.
- Confirm your commercial or Medicare-Advantage insurance.
- Gather BMI + weight history + comorbidity data.
- Decide your GLP-1 target: Wegovy / Zepbound (weight) or Ozempic / Mounjaro (T2D).
- Read Terms of Use + Telehealth Consent.
- Complete intake at lifemd.com/weight-management.
After sign-up
- Schedule clinician video visit.
- LifeMD insurance team submits PA to your plan.
- Receive FDA-approved GLP-1 prescription once PA approved.
- Download LifeMD app (iOS / Android).
- Attend monthly follow-ups for dose titration + side-effect management.
- Track progress via the app.
Canceling LifeMD
- Review Terms of Use at lifemd.com/terms.
- Contact Member Support via the app, email, or phone.
- Cancel a few days before next $79 billing.
- Request written cancellation confirmation.
- Discuss GLP-1 off-ramp with your LifeMD clinician — don't dispose of remaining medication abruptly.
LifeMD GLP-1 frequently asked questions
How much does LifeMD's GLP-1 program cost in 2026?
$79/month Weight Management Program subscription (typical three-month minimum). Medication priced separately and coordinated through insurance. Out-of-pocket depends on plan benefits and prior-authorization outcome.
Is LifeMD's GLP-1 program legit?
Yes — LifeMD, Inc. is publicly traded on Nasdaq under LFMD with full SEC reporting. NCQA Patient-Centered Connected Care recognized. Named CMO Dr. Anthony Puopolo MD. Comprehensive Terms + Privacy + Telehealth Consent + Notice of Privacy Practices published.
What GLP-1 medications does LifeMD offer?
FDA-approved branded: Wegovy (sema) + Zepbound (tirz) + Ozempic (sema) + Mounjaro (tirz). Wegovy + Zepbound are FDA-approved for weight management; Ozempic + Mounjaro are FDA-approved for type 2 diabetes and require clinical eligibility.
Does LifeMD handle insurance for GLP-1?
Yes — LifeMD runs a dedicated in-house insurance navigation team that prepares and submits prior-authorization paperwork to commercial and Medicare-Advantage plans on FDA-approved Wegovy, Zepbound, Ozempic, and Mounjaro.
How does LifeMD's weight management program work?
Intake → clinician video visit → insurance prior authorization → pharmacy fulfillment → ongoing monthly app-based follow-up at $79/month.
Is LifeMD available in all 50 U.S. states?
Yes — all 50 states plus Washington D.C., supported by a board-certified U.S. clinician network.
Who is the LifeMD Chief Medical Officer?
Dr. Anthony Puopolo, MD. Board-certified family medicine. Editorial reviewer Dr. Naheed Ali MD PhD also publicly disclosed.
What other services does LifeMD offer beyond GLP-1?
Primary Care + Mental Health + Men's Health + Hair Loss + Skin + Insomnia + Allergy + B12 + Cold Sore + LifeMD Concierge.
How do I cancel LifeMD's Weight Management Program?
Via the LifeMD app, email, or phone. Cancel a few days before the next $79 billing. Discuss medication off-ramp with your clinician before stopping.
Does LifeMD offer compounded GLP-1?
LifeMD's GLP-1 model is FDA-approved branded only. Compounded semaglutide / tirzepatide is not the platform's primary path. Standard FDA disclosure applies to any compounded option: "Compounded products are not approved nor evaluated for safety, efficacy, or quality by the FDA."
Honest verdict — should you choose LifeMD?
LifeMD earns its 4.4/5 GLP-1 editor's rating on five distinctive features. First: Nasdaq-listed parent (LifeMD, Inc., LFMD) with SEC reporting and corporate-governance transparency. Second: NCQA Patient-Centered Connected Care recognition — a mainstream healthcare accreditation. Third: dedicated in-house insurance navigation team that handles Wegovy / Zepbound / Ozempic / Mounjaro prior authorization for commercial and Medicare-Advantage plans. Fourth: named medical leadership including Chief Medical Officer Dr. Anthony Puopolo MD. Fifth: broader integrated telehealth menu (Primary Care + Mental Health + Men's Health + Hair + Skin + Insomnia + Allergy + B12 + Concierge) — GLP-1 sits inside a multi-vertical clinical platform.
The bottom line
If you have commercial or Medicare-Advantage insurance and value Nasdaq-listed parent infrastructure + NCQA recognition + active prior-authorization handling + named medical leadership, LifeMD is editorially compelling. If you want the absolute cheapest cash-pay compounded GLP-1 without subscription overhead or insurance coordination, the platform may not be the best structural fit.
Start with LifeMD today
Nasdaq: LFMD. NCQA. Dedicated insurance navigation. FDA-approved-only GLP-1.
Visit LifeMD's Official Site →Published: June 11, 2026 · Verified: June 2026 · Spot a factual issue? Tell our editors.